GlassScriptPhysician profile
Abu N Ahmed
NPI 1740287515
$2,607.89
in general payments reported to CMS, 2019-2025
43 companies · $456 in 2025
The $456 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $77.17 · 2021: $349 · 2022: $666 · 2023: $509 · 2024: $276 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.82 |
| Education | $277.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $346.50 | 2019-2025 | Padcev |
| Novartis Pharmaceuticals Corporation | $276.02 | 2019-2025 | |
| Shockwave Medical, INC | $258.72 | 2022 | |
| Janssen Biotech, INC. | $209.43 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Abbvie INC. | $143.13 | 2021-2023 | Qulipta, Ubrelvy, Venclexta |
| Pfizer INC. | $132.14 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $118.39 | 2019-2023 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $100.13 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Glaxosmithkline, LLC. | $77.27 | 2021-2024 | Zejula, Jemperli |
| Dendreon Pharmaceuticals LLC | $54.83 | 2019-2022 | |
| Daiichi Sankyo INC. | $49.69 | 2021-2022 | |
| Beone Medicines USA, INC. | $46.87 | 2025 | Tevimbra, Brukinsa |
| Beigene USA, INC. | $46.75 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $40.74 | 2023-2024 | Orgovyx |
| Servier Pharmaceuticals LLC | $39.36 | 2022-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abu Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.